nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—CYP3A4—Topotecan—lung cancer	0.0594	0.142	CbGbCtD
Methylergometrine—CYP3A4—Gefitinib—lung cancer	0.0543	0.13	CbGbCtD
Methylergometrine—CYP3A4—Teniposide—lung cancer	0.0527	0.126	CbGbCtD
Methylergometrine—CYP3A4—Vinorelbine—lung cancer	0.0418	0.1	CbGbCtD
Methylergometrine—CYP3A4—Crizotinib—lung cancer	0.0333	0.0796	CbGbCtD
Methylergometrine—CYP3A4—Erlotinib—lung cancer	0.0321	0.0768	CbGbCtD
Methylergometrine—CYP3A4—Paclitaxel—lung cancer	0.0294	0.0703	CbGbCtD
Methylergometrine—CYP3A4—Irinotecan—lung cancer	0.029	0.0694	CbGbCtD
Methylergometrine—CYP3A4—Vinblastine—lung cancer	0.0258	0.0617	CbGbCtD
Methylergometrine—CYP3A4—Etoposide—lung cancer	0.0232	0.0555	CbGbCtD
Methylergometrine—CYP3A4—Docetaxel—lung cancer	0.0213	0.0508	CbGbCtD
Methylergometrine—CYP3A4—Doxorubicin—lung cancer	0.0158	0.0379	CbGbCtD
Methylergometrine—HTR2A—phrenic nerve—lung cancer	0.00883	0.604	CbGeAlD
Methylergometrine—HTR2A—pulmonary artery—lung cancer	0.0032	0.219	CbGeAlD
Methylergometrine—Diarrhoea—Gefitinib—lung cancer	0.00176	0.00463	CcSEcCtD
Methylergometrine—Cardiac disorder—Vinorelbine—lung cancer	0.00174	0.00457	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Teniposide—lung cancer	0.00172	0.00451	CcSEcCtD
Methylergometrine—Dizziness—Pemetrexed—lung cancer	0.00171	0.00451	CcSEcCtD
Methylergometrine—Sweating increased—Cisplatin—lung cancer	0.00171	0.00449	CcSEcCtD
Methylergometrine—Convulsion—Vinblastine—lung cancer	0.0017	0.00447	CcSEcCtD
Methylergometrine—Hypertension—Vinblastine—lung cancer	0.00169	0.00446	CcSEcCtD
Methylergometrine—Nausea—Crizotinib—lung cancer	0.00168	0.00443	CcSEcCtD
Methylergometrine—Abdominal pain—Teniposide—lung cancer	0.00166	0.00436	CcSEcCtD
Methylergometrine—Vomiting—Pemetrexed—lung cancer	0.00165	0.00433	CcSEcCtD
Methylergometrine—Vomiting—Gefitinib—lung cancer	0.00164	0.00431	CcSEcCtD
Methylergometrine—Rash—Pemetrexed—lung cancer	0.00163	0.0043	CcSEcCtD
Methylergometrine—Dermatitis—Pemetrexed—lung cancer	0.00163	0.00429	CcSEcCtD
Methylergometrine—Rash—Gefitinib—lung cancer	0.00162	0.00427	CcSEcCtD
Methylergometrine—Chest pain—Topotecan—lung cancer	0.00162	0.00427	CcSEcCtD
Methylergometrine—Dermatitis—Gefitinib—lung cancer	0.00162	0.00427	CcSEcCtD
Methylergometrine—Chest pain—Erlotinib—lung cancer	0.00161	0.00422	CcSEcCtD
Methylergometrine—Haematuria—Gemcitabine—lung cancer	0.0016	0.0042	CcSEcCtD
Methylergometrine—Bradycardia—Irinotecan—lung cancer	0.00157	0.00414	CcSEcCtD
Methylergometrine—Sweating increased—Etoposide—lung cancer	0.00156	0.00411	CcSEcCtD
Methylergometrine—Anaphylactic shock—Topotecan—lung cancer	0.00156	0.00409	CcSEcCtD
Methylergometrine—Nausea—Pemetrexed—lung cancer	0.00154	0.00405	CcSEcCtD
Methylergometrine—Sweating increased—Paclitaxel—lung cancer	0.00153	0.00403	CcSEcCtD
Methylergometrine—Nausea—Gefitinib—lung cancer	0.00153	0.00402	CcSEcCtD
Methylergometrine—Nervous system disorder—Topotecan—lung cancer	0.00153	0.00401	CcSEcCtD
Methylergometrine—Nervous system disorder—Erlotinib—lung cancer	0.00151	0.00397	CcSEcCtD
Methylergometrine—Hyperhidrosis—Topotecan—lung cancer	0.0015	0.00396	CcSEcCtD
Methylergometrine—Palpitations—Vinorelbine—lung cancer	0.00144	0.00379	CcSEcCtD
Methylergometrine—Paraesthesia—Vinblastine—lung cancer	0.00144	0.00378	CcSEcCtD
Methylergometrine—Diarrhoea—Teniposide—lung cancer	0.00144	0.00378	CcSEcCtD
Methylergometrine—Cardiac disorder—Irinotecan—lung cancer	0.00143	0.00377	CcSEcCtD
Methylergometrine—Bradycardia—Cisplatin—lung cancer	0.00143	0.00376	CcSEcCtD
Methylergometrine—Hypertension—Vinorelbine—lung cancer	0.00141	0.0037	CcSEcCtD
Methylergometrine—Paraesthesia—Topotecan—lung cancer	0.0014	0.00367	CcSEcCtD
Methylergometrine—Cardiac disorder—Gemcitabine—lung cancer	0.0014	0.00367	CcSEcCtD
Methylergometrine—Chest pain—Vinorelbine—lung cancer	0.00139	0.00365	CcSEcCtD
Methylergometrine—Dyspnoea—Topotecan—lung cancer	0.00139	0.00365	CcSEcCtD
Methylergometrine—Dyspnoea—Erlotinib—lung cancer	0.00137	0.00361	CcSEcCtD
Methylergometrine—Atrioventricular block—Doxorubicin—lung cancer	0.00137	0.0036	CcSEcCtD
Methylergometrine—Haematuria—Paclitaxel—lung cancer	0.00134	0.00352	CcSEcCtD
Methylergometrine—Vomiting—Teniposide—lung cancer	0.00133	0.00351	CcSEcCtD
Methylergometrine—Anaphylactic shock—Vinorelbine—lung cancer	0.00133	0.0035	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Doxorubicin—lung cancer	0.00133	0.00349	CcSEcCtD
Methylergometrine—Rash—Teniposide—lung cancer	0.00132	0.00348	CcSEcCtD
Methylergometrine—Dermatitis—Teniposide—lung cancer	0.00132	0.00348	CcSEcCtD
Methylergometrine—Headache—Teniposide—lung cancer	0.00132	0.00346	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Vinblastine—lung cancer	0.00131	0.00344	CcSEcCtD
Methylergometrine—Tinnitus—Cisplatin—lung cancer	0.00131	0.00344	CcSEcCtD
Methylergometrine—Nervous system disorder—Vinorelbine—lung cancer	0.00131	0.00343	CcSEcCtD
Methylergometrine—Cardiac disorder—Cisplatin—lung cancer	0.0013	0.00342	CcSEcCtD
Methylergometrine—Angina pectoris—Docetaxel—lung cancer	0.0013	0.00342	CcSEcCtD
Methylergometrine—Tachycardia—Vinorelbine—lung cancer	0.0013	0.00342	CcSEcCtD
Methylergometrine—Muscle spasms—Irinotecan—lung cancer	0.00129	0.0034	CcSEcCtD
Methylergometrine—Thrombophlebitis—Methotrexate—lung cancer	0.00129	0.00338	CcSEcCtD
Methylergometrine—Bradycardia—Paclitaxel—lung cancer	0.00128	0.00337	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Topotecan—lung cancer	0.00127	0.00335	CcSEcCtD
Methylergometrine—Abdominal pain—Vinblastine—lung cancer	0.00127	0.00333	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Erlotinib—lung cancer	0.00126	0.00331	CcSEcCtD
Methylergometrine—Nausea—Teniposide—lung cancer	0.00125	0.00328	CcSEcCtD
Methylergometrine—Hypotension—Vinorelbine—lung cancer	0.00124	0.00327	CcSEcCtD
Methylergometrine—Abdominal pain—Topotecan—lung cancer	0.00123	0.00323	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Doxorubicin—lung cancer	0.00122	0.00321	CcSEcCtD
Methylergometrine—Abdominal pain—Erlotinib—lung cancer	0.00122	0.0032	CcSEcCtD
Methylergometrine—Paraesthesia—Vinorelbine—lung cancer	0.0012	0.00314	CcSEcCtD
Methylergometrine—Cardiac disorder—Etoposide—lung cancer	0.00119	0.00314	CcSEcCtD
Methylergometrine—Dyspnoea—Vinorelbine—lung cancer	0.00119	0.00312	CcSEcCtD
Methylergometrine—Tinnitus—Paclitaxel—lung cancer	0.00117	0.00309	CcSEcCtD
Methylergometrine—Muscle spasms—Cisplatin—lung cancer	0.00117	0.00309	CcSEcCtD
Methylergometrine—Cardiac disorder—Paclitaxel—lung cancer	0.00117	0.00308	CcSEcCtD
Methylergometrine—Hypertension—Irinotecan—lung cancer	0.00116	0.00305	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Methotrexate—lung cancer	0.00114	0.00299	CcSEcCtD
Methylergometrine—Hypertension—Gemcitabine—lung cancer	0.00113	0.00297	CcSEcCtD
Methylergometrine—Chest pain—Gemcitabine—lung cancer	0.00112	0.00293	CcSEcCtD
Methylergometrine—Thrombophlebitis—Doxorubicin—lung cancer	0.00111	0.00293	CcSEcCtD
Methylergometrine—Anaphylactic shock—Irinotecan—lung cancer	0.0011	0.00289	CcSEcCtD
Methylergometrine—Diarrhoea—Vinblastine—lung cancer	0.0011	0.00288	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Vinorelbine—lung cancer	0.00109	0.00286	CcSEcCtD
Methylergometrine—Nervous system disorder—Irinotecan—lung cancer	0.00108	0.00283	CcSEcCtD
Methylergometrine—Muscle spasms—Etoposide—lung cancer	0.00108	0.00283	CcSEcCtD
Methylergometrine—Anaphylactic shock—Gemcitabine—lung cancer	0.00107	0.00281	CcSEcCtD
Methylergometrine—Diarrhoea—Topotecan—lung cancer	0.00106	0.0028	CcSEcCtD
Methylergometrine—Hyperhidrosis—Irinotecan—lung cancer	0.00106	0.00279	CcSEcCtD
Methylergometrine—Dizziness—Vinblastine—lung cancer	0.00106	0.00279	CcSEcCtD
Methylergometrine—Convulsion—Cisplatin—lung cancer	0.00106	0.00278	CcSEcCtD
Methylergometrine—Muscle spasms—Paclitaxel—lung cancer	0.00105	0.00277	CcSEcCtD
Methylergometrine—Diarrhoea—Erlotinib—lung cancer	0.00105	0.00277	CcSEcCtD
Methylergometrine—Abdominal pain—Vinorelbine—lung cancer	0.00105	0.00277	CcSEcCtD
Methylergometrine—Nervous system disorder—Gemcitabine—lung cancer	0.00105	0.00276	CcSEcCtD
Methylergometrine—Hyperhidrosis—Gemcitabine—lung cancer	0.00103	0.00272	CcSEcCtD
Methylergometrine—Dizziness—Topotecan—lung cancer	0.00103	0.00271	CcSEcCtD
Methylergometrine—Hypotension—Irinotecan—lung cancer	0.00103	0.0027	CcSEcCtD
Methylergometrine—Vomiting—Vinblastine—lung cancer	0.00102	0.00268	CcSEcCtD
Methylergometrine—Dizziness—Erlotinib—lung cancer	0.00102	0.00268	CcSEcCtD
Methylergometrine—Headache—Vinblastine—lung cancer	0.001	0.00264	CcSEcCtD
Methylergometrine—Hypotension—Gemcitabine—lung cancer	0.000999	0.00263	CcSEcCtD
Methylergometrine—Anaphylactic shock—Cisplatin—lung cancer	0.000997	0.00262	CcSEcCtD
Methylergometrine—Cardiac disorder—Docetaxel—lung cancer	0.000991	0.00261	CcSEcCtD
Methylergometrine—Vomiting—Topotecan—lung cancer	0.000989	0.0026	CcSEcCtD
Methylergometrine—Paraesthesia—Irinotecan—lung cancer	0.000986	0.00259	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Doxorubicin—lung cancer	0.000983	0.00259	CcSEcCtD
Methylergometrine—Rash—Topotecan—lung cancer	0.000981	0.00258	CcSEcCtD
Methylergometrine—Dermatitis—Topotecan—lung cancer	0.00098	0.00258	CcSEcCtD
Methylergometrine—Vomiting—Erlotinib—lung cancer	0.000979	0.00257	CcSEcCtD
Methylergometrine—Dyspnoea—Irinotecan—lung cancer	0.000979	0.00257	CcSEcCtD
Methylergometrine—Nervous system disorder—Cisplatin—lung cancer	0.000977	0.00257	CcSEcCtD
Methylergometrine—Headache—Topotecan—lung cancer	0.000975	0.00256	CcSEcCtD
Methylergometrine—Tachycardia—Cisplatin—lung cancer	0.000973	0.00256	CcSEcCtD
Methylergometrine—Rash—Erlotinib—lung cancer	0.000971	0.00255	CcSEcCtD
Methylergometrine—Dermatitis—Erlotinib—lung cancer	0.00097	0.00255	CcSEcCtD
Methylergometrine—Palpitations—Paclitaxel—lung cancer	0.000969	0.00255	CcSEcCtD
Methylergometrine—Convulsion—Etoposide—lung cancer	0.000969	0.00255	CcSEcCtD
Methylergometrine—Hypertension—Etoposide—lung cancer	0.000966	0.00254	CcSEcCtD
Methylergometrine—Headache—Erlotinib—lung cancer	0.000964	0.00254	CcSEcCtD
Methylergometrine—Hyperhidrosis—Cisplatin—lung cancer	0.000964	0.00253	CcSEcCtD
Methylergometrine—Paraesthesia—Gemcitabine—lung cancer	0.00096	0.00252	CcSEcCtD
Methylergometrine—Dyspnoea—Gemcitabine—lung cancer	0.000953	0.00251	CcSEcCtD
Methylergometrine—Chest pain—Etoposide—lung cancer	0.000952	0.0025	CcSEcCtD
Methylergometrine—Nausea—Vinblastine—lung cancer	0.000951	0.0025	CcSEcCtD
Methylergometrine—Convulsion—Paclitaxel—lung cancer	0.00095	0.0025	CcSEcCtD
Methylergometrine—Hypertension—Paclitaxel—lung cancer	0.000947	0.00249	CcSEcCtD
Methylergometrine—Chest pain—Paclitaxel—lung cancer	0.000934	0.00246	CcSEcCtD
Methylergometrine—Hypotension—Cisplatin—lung cancer	0.000931	0.00245	CcSEcCtD
Methylergometrine—Nausea—Topotecan—lung cancer	0.000924	0.00243	CcSEcCtD
Methylergometrine—Nausea—Erlotinib—lung cancer	0.000914	0.0024	CcSEcCtD
Methylergometrine—Anaphylactic shock—Etoposide—lung cancer	0.000913	0.0024	CcSEcCtD
Methylergometrine—Diarrhoea—Vinorelbine—lung cancer	0.000911	0.00239	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Irinotecan—lung cancer	0.000898	0.00236	CcSEcCtD
Methylergometrine—Anaphylactic shock—Paclitaxel—lung cancer	0.000895	0.00235	CcSEcCtD
Methylergometrine—Paraesthesia—Cisplatin—lung cancer	0.000895	0.00235	CcSEcCtD
Methylergometrine—Muscle spasms—Docetaxel—lung cancer	0.000894	0.00235	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—lung cancer	0.000891	0.00234	CcSEcCtD
Methylergometrine—Dyspnoea—Cisplatin—lung cancer	0.000889	0.00234	CcSEcCtD
Methylergometrine—Hyperhidrosis—Etoposide—lung cancer	0.000883	0.00232	CcSEcCtD
Methylergometrine—Dizziness—Vinorelbine—lung cancer	0.00088	0.00231	CcSEcCtD
Methylergometrine—Nervous system disorder—Paclitaxel—lung cancer	0.000878	0.00231	CcSEcCtD
Methylergometrine—Tachycardia—Paclitaxel—lung cancer	0.000874	0.0023	CcSEcCtD
Methylergometrine—Abdominal pain—Irinotecan—lung cancer	0.000868	0.00228	CcSEcCtD
Methylergometrine—Hyperhidrosis—Paclitaxel—lung cancer	0.000865	0.00228	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—lung cancer	0.000853	0.00224	CcSEcCtD
Methylergometrine—Vomiting—Vinorelbine—lung cancer	0.000846	0.00223	CcSEcCtD
Methylergometrine—Rash—Vinorelbine—lung cancer	0.000839	0.00221	CcSEcCtD
Methylergometrine—Dermatitis—Vinorelbine—lung cancer	0.000838	0.0022	CcSEcCtD
Methylergometrine—Hypotension—Paclitaxel—lung cancer	0.000837	0.0022	CcSEcCtD
Methylergometrine—Headache—Vinorelbine—lung cancer	0.000834	0.00219	CcSEcCtD
Methylergometrine—Palpitations—Docetaxel—lung cancer	0.000822	0.00216	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—lung cancer	0.00082	0.00216	CcSEcCtD
Methylergometrine—Haematuria—Methotrexate—lung cancer	0.000818	0.00215	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—lung cancer	0.000814	0.00214	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—lung cancer	0.000811	0.00213	CcSEcCtD
Methylergometrine—Convulsion—Docetaxel—lung cancer	0.000806	0.00212	CcSEcCtD
Methylergometrine—Paraesthesia—Paclitaxel—lung cancer	0.000804	0.00211	CcSEcCtD
Methylergometrine—Hypertension—Docetaxel—lung cancer	0.000803	0.00211	CcSEcCtD
Methylergometrine—Dyspnoea—Paclitaxel—lung cancer	0.000798	0.0021	CcSEcCtD
Methylergometrine—Chest pain—Docetaxel—lung cancer	0.000792	0.00208	CcSEcCtD
Methylergometrine—Nausea—Vinorelbine—lung cancer	0.000791	0.00208	CcSEcCtD
Methylergometrine—Anaphylactic shock—Docetaxel—lung cancer	0.000759	0.002	CcSEcCtD
Methylergometrine—Diarrhoea—Irinotecan—lung cancer	0.000751	0.00198	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—lung cancer	0.000747	0.00196	CcSEcCtD
Methylergometrine—Nervous system disorder—Docetaxel—lung cancer	0.000744	0.00196	CcSEcCtD
Methylergometrine—Tachycardia—Docetaxel—lung cancer	0.000741	0.00195	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000732	0.00193	CcSEcCtD
Methylergometrine—Diarrhoea—Gemcitabine—lung cancer	0.000732	0.00192	CcSEcCtD
Methylergometrine—Dizziness—Irinotecan—lung cancer	0.000726	0.00191	CcSEcCtD
Methylergometrine—Abdominal pain—Etoposide—lung cancer	0.000722	0.0019	CcSEcCtD
Methylergometrine—Tinnitus—Methotrexate—lung cancer	0.000718	0.00189	CcSEcCtD
Methylergometrine—Cardiac disorder—Methotrexate—lung cancer	0.000714	0.00188	CcSEcCtD
Methylergometrine—Hypotension—Docetaxel—lung cancer	0.000709	0.00186	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—lung cancer	0.000708	0.00186	CcSEcCtD
Methylergometrine—Abdominal pain—Paclitaxel—lung cancer	0.000708	0.00186	CcSEcCtD
Methylergometrine—Vomiting—Irinotecan—lung cancer	0.000698	0.00184	CcSEcCtD
Methylergometrine—Ergonovine—ABCB1—lung cancer	0.000696	0.475	CrCbGaD
Methylergometrine—Rash—Irinotecan—lung cancer	0.000692	0.00182	CcSEcCtD
Methylergometrine—Dermatitis—Irinotecan—lung cancer	0.000691	0.00182	CcSEcCtD
Methylergometrine—Headache—Irinotecan—lung cancer	0.000688	0.00181	CcSEcCtD
Methylergometrine—Diarrhoea—Cisplatin—lung cancer	0.000682	0.00179	CcSEcCtD
Methylergometrine—Paraesthesia—Docetaxel—lung cancer	0.000681	0.00179	CcSEcCtD
Methylergometrine—Vomiting—Gemcitabine—lung cancer	0.00068	0.00179	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—lung cancer	0.000679	0.00178	CcSEcCtD
Methylergometrine—Dyspnoea—Docetaxel—lung cancer	0.000677	0.00178	CcSEcCtD
Methylergometrine—Rash—Gemcitabine—lung cancer	0.000674	0.00177	CcSEcCtD
Methylergometrine—Dermatitis—Gemcitabine—lung cancer	0.000674	0.00177	CcSEcCtD
Methylergometrine—Headache—Gemcitabine—lung cancer	0.00067	0.00176	CcSEcCtD
Methylergometrine—Nausea—Irinotecan—lung cancer	0.000652	0.00171	CcSEcCtD
Methylergometrine—Nausea—Gemcitabine—lung cancer	0.000635	0.00167	CcSEcCtD
Methylergometrine—Vomiting—Cisplatin—lung cancer	0.000634	0.00167	CcSEcCtD
Methylergometrine—Rash—Cisplatin—lung cancer	0.000628	0.00165	CcSEcCtD
Methylergometrine—Dermatitis—Cisplatin—lung cancer	0.000628	0.00165	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—lung cancer	0.000625	0.00164	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—lung cancer	0.000621	0.00163	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Docetaxel—lung cancer	0.000621	0.00163	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—lung cancer	0.000619	0.00163	CcSEcCtD
Methylergometrine—Diarrhoea—Paclitaxel—lung cancer	0.000613	0.00161	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—lung cancer	0.000604	0.00159	CcSEcCtD
Methylergometrine—Abdominal pain—Docetaxel—lung cancer	0.0006	0.00158	CcSEcCtD
Methylergometrine—Dizziness—Paclitaxel—lung cancer	0.000592	0.00156	CcSEcCtD
Methylergometrine—Nausea—Cisplatin—lung cancer	0.000592	0.00156	CcSEcCtD
Methylergometrine—Convulsion—Methotrexate—lung cancer	0.000581	0.00153	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—lung cancer	0.000581	0.00153	CcSEcCtD
Methylergometrine—Rash—Etoposide—lung cancer	0.000576	0.00151	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—lung cancer	0.000575	0.00151	CcSEcCtD
Methylergometrine—Headache—Etoposide—lung cancer	0.000572	0.0015	CcSEcCtD
Methylergometrine—Chest pain—Methotrexate—lung cancer	0.000571	0.0015	CcSEcCtD
Methylergometrine—Vomiting—Paclitaxel—lung cancer	0.000569	0.0015	CcSEcCtD
Methylergometrine—Rash—Paclitaxel—lung cancer	0.000564	0.00148	CcSEcCtD
Methylergometrine—Dermatitis—Paclitaxel—lung cancer	0.000564	0.00148	CcSEcCtD
Methylergometrine—Headache—Paclitaxel—lung cancer	0.000561	0.00147	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—lung cancer	0.000558	0.00147	CcSEcCtD
Methylergometrine—Anaphylactic shock—Methotrexate—lung cancer	0.000547	0.00144	CcSEcCtD
Methylergometrine—Nausea—Etoposide—lung cancer	0.000542	0.00143	CcSEcCtD
Methylergometrine—HTR2A—respiratory system—lung cancer	0.000539	0.0369	CbGeAlD
Methylergometrine—Nervous system disorder—Methotrexate—lung cancer	0.000536	0.00141	CcSEcCtD
Methylergometrine—HTR2B—lung—lung cancer	0.000536	0.0367	CbGeAlD
Methylergometrine—Nausea—Paclitaxel—lung cancer	0.000532	0.0014	CcSEcCtD
Methylergometrine—Hyperhidrosis—Methotrexate—lung cancer	0.000529	0.00139	CcSEcCtD
Methylergometrine—Diarrhoea—Docetaxel—lung cancer	0.000519	0.00137	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—lung cancer	0.000513	0.00135	CcSEcCtD
Methylergometrine—Hypotension—Methotrexate—lung cancer	0.000511	0.00134	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—lung cancer	0.000503	0.00132	CcSEcCtD
Methylergometrine—Dizziness—Docetaxel—lung cancer	0.000502	0.00132	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—lung cancer	0.000501	0.00132	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—lung cancer	0.000494	0.0013	CcSEcCtD
Methylergometrine—Paraesthesia—Methotrexate—lung cancer	0.000491	0.00129	CcSEcCtD
Methylergometrine—Dyspnoea—Methotrexate—lung cancer	0.000488	0.00128	CcSEcCtD
Methylergometrine—Vomiting—Docetaxel—lung cancer	0.000482	0.00127	CcSEcCtD
Methylergometrine—Rash—Docetaxel—lung cancer	0.000478	0.00126	CcSEcCtD
Methylergometrine—Dermatitis—Docetaxel—lung cancer	0.000478	0.00126	CcSEcCtD
Methylergometrine—Headache—Docetaxel—lung cancer	0.000475	0.00125	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—lung cancer	0.000474	0.00125	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—lung cancer	0.000464	0.00122	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—lung cancer	0.000462	0.00122	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—lung cancer	0.000458	0.0012	CcSEcCtD
Methylergometrine—Nausea—Docetaxel—lung cancer	0.000451	0.00119	CcSEcCtD
Methylergometrine—HTR2A—epithelium—lung cancer	0.00045	0.0308	CbGeAlD
Methylergometrine—Gastrointestinal pain—Methotrexate—lung cancer	0.000447	0.00118	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—lung cancer	0.000443	0.00116	CcSEcCtD
Methylergometrine—Abdominal pain—Methotrexate—lung cancer	0.000432	0.00114	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—lung cancer	0.000425	0.00112	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—lung cancer	0.000422	0.00111	CcSEcCtD
Methylergometrine—HTR2A—trachea—lung cancer	0.000398	0.0273	CbGeAlD
Methylergometrine—Ergotamine—ABCB1—lung cancer	0.000392	0.267	CrCbGaD
Methylergometrine—Gastrointestinal pain—Doxorubicin—lung cancer	0.000387	0.00102	CcSEcCtD
Methylergometrine—Bromocriptine—ABCB1—lung cancer	0.000378	0.258	CrCbGaD
Methylergometrine—Abdominal pain—Doxorubicin—lung cancer	0.000374	0.000984	CcSEcCtD
Methylergometrine—Diarrhoea—Methotrexate—lung cancer	0.000374	0.000984	CcSEcCtD
Methylergometrine—HTR2B—lymph node—lung cancer	0.000367	0.0251	CbGeAlD
Methylergometrine—Dizziness—Methotrexate—lung cancer	0.000362	0.000951	CcSEcCtD
Methylergometrine—Vomiting—Methotrexate—lung cancer	0.000348	0.000914	CcSEcCtD
Methylergometrine—Rash—Methotrexate—lung cancer	0.000345	0.000907	CcSEcCtD
Methylergometrine—Dermatitis—Methotrexate—lung cancer	0.000345	0.000906	CcSEcCtD
Methylergometrine—Headache—Methotrexate—lung cancer	0.000343	0.000901	CcSEcCtD
Methylergometrine—Nausea—Methotrexate—lung cancer	0.000325	0.000854	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—lung cancer	0.000324	0.000852	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—lung cancer	0.000313	0.000824	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—lung cancer	0.000301	0.000792	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—lung cancer	0.000299	0.000785	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—lung cancer	0.000298	0.000785	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—lung cancer	0.000297	0.00078	CcSEcCtD
Methylergometrine—HTR2A—lung—lung cancer	0.000286	0.0196	CbGeAlD
Methylergometrine—Nausea—Doxorubicin—lung cancer	0.000281	0.00074	CcSEcCtD
Methylergometrine—DRD1—Signaling Pathways—KIT—lung cancer	3.16e-05	0.00017	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—NRAS—lung cancer	3.16e-05	0.00017	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—BRAF—lung cancer	3.15e-05	0.00017	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MYC—lung cancer	3.13e-05	0.000169	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGF—lung cancer	3.12e-05	0.000168	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—RAF1—lung cancer	3.11e-05	0.000168	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—FGFR1—lung cancer	3.11e-05	0.000168	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6R—lung cancer	3.11e-05	0.000168	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTA2—lung cancer	3.11e-05	0.000168	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CREBBP—lung cancer	3.1e-05	0.000167	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—IL2—lung cancer	3.08e-05	0.000166	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HIF1A—lung cancer	3.06e-05	0.000165	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—EGFR—lung cancer	3.06e-05	0.000165	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—EGFR—lung cancer	3.05e-05	0.000164	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CB—lung cancer	3.04e-05	0.000164	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MAPK3—lung cancer	3.04e-05	0.000164	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—MAPK3—lung cancer	3.02e-05	0.000163	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—POMC—lung cancer	3e-05	0.000162	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTA1—lung cancer	3e-05	0.000162	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—BRAF—lung cancer	2.97e-05	0.00016	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCC3—lung cancer	2.96e-05	0.00016	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAP2K1—lung cancer	2.96e-05	0.00016	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOA1—lung cancer	2.96e-05	0.000159	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—lung cancer	2.95e-05	0.000159	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CD—lung cancer	2.94e-05	0.000159	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KDR—lung cancer	2.93e-05	0.000158	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6R—lung cancer	2.93e-05	0.000158	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CREBBP—lung cancer	2.93e-05	0.000158	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCL8—lung cancer	2.92e-05	0.000158	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—PIK3CA—lung cancer	2.91e-05	0.000157	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB3—lung cancer	2.9e-05	0.000157	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—KRAS—lung cancer	2.89e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—EGFR—lung cancer	2.89e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—KRAS—lung cancer	2.88e-05	0.000155	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—EGFR—lung cancer	2.88e-05	0.000155	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKR1C1—lung cancer	2.87e-05	0.000155	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL2—lung cancer	2.79e-05	0.000151	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAP2K1—lung cancer	2.79e-05	0.000151	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—UGT1A1—lung cancer	2.79e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TERT—lung cancer	2.78e-05	0.00015	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CD—lung cancer	2.77e-05	0.00015	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—PIK3CA—lung cancer	2.75e-05	0.000148	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—KRAS—lung cancer	2.73e-05	0.000147	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—KRAS—lung cancer	2.72e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—FGFR1—lung cancer	2.7e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KIT—lung cancer	2.7e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—lung cancer	2.7e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APC—lung cancer	2.7e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—NRAS—lung cancer	2.7e-05	0.000146	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GNG11—lung cancer	2.69e-05	0.000145	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGF—lung cancer	2.67e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HIF1A—lung cancer	2.66e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PIK3CA—lung cancer	2.66e-05	0.000143	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PIK3CA—lung cancer	2.65e-05	0.000143	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MDM2—lung cancer	2.64e-05	0.000142	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—RAF1—lung cancer	2.63e-05	0.000142	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ERBB2—lung cancer	2.6e-05	0.00014	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—MAPK3—lung cancer	2.59e-05	0.000139	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—lung cancer	2.57e-05	0.000139	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—POMC—lung cancer	2.57e-05	0.000139	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOA1—lung cancer	2.57e-05	0.000139	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MTOR—lung cancer	2.56e-05	0.000138	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CB—lung cancer	2.56e-05	0.000138	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALDOA—lung cancer	2.56e-05	0.000138	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KDR—lung cancer	2.54e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—BRAF—lung cancer	2.54e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PIK3CA—lung cancer	2.51e-05	0.000135	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6R—lung cancer	2.51e-05	0.000135	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CREBBP—lung cancer	2.5e-05	0.000135	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PIK3CA—lung cancer	2.5e-05	0.000135	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MDM2—lung cancer	2.49e-05	0.000134	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NCOA3—lung cancer	2.48e-05	0.000134	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—RAF1—lung cancer	2.48e-05	0.000134	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCL8—lung cancer	2.46e-05	0.000133	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—EGFR—lung cancer	2.46e-05	0.000133	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—HRAS—lung cancer	2.46e-05	0.000133	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ERBB2—lung cancer	2.45e-05	0.000132	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—HRAS—lung cancer	2.45e-05	0.000132	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—lung cancer	2.43e-05	0.000131	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MTOR—lung cancer	2.42e-05	0.00013	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CB—lung cancer	2.42e-05	0.00013	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ADCY1—lung cancer	2.42e-05	0.00013	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCG2—lung cancer	2.42e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAP2K1—lung cancer	2.39e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—lung cancer	2.38e-05	0.000128	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CD—lung cancer	2.37e-05	0.000128	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ENO2—lung cancer	2.37e-05	0.000128	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HPGDS—lung cancer	2.37e-05	0.000128	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—lung cancer	2.36e-05	0.000127	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL2—lung cancer	2.35e-05	0.000127	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPP2R1B—lung cancer	2.35e-05	0.000127	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—lung cancer	2.35e-05	0.000127	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	2.35e-05	0.000127	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APC—lung cancer	2.34e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—lung cancer	2.34e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KIT—lung cancer	2.34e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—NRAS—lung cancer	2.34e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—lung cancer	2.34e-05	0.000126	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCL8—lung cancer	2.32e-05	0.000125	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—KRAS—lung cancer	2.32e-05	0.000125	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HRAS—lung cancer	2.32e-05	0.000125	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGF—lung cancer	2.32e-05	0.000125	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—HRAS—lung cancer	2.31e-05	0.000125	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTT1—lung cancer	2.3e-05	0.000124	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCND1—lung cancer	2.3e-05	0.000124	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—JUN—lung cancer	2.29e-05	0.000124	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GCLC—lung cancer	2.27e-05	0.000122	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2A6—lung cancer	2.27e-05	0.000122	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—MAPK3—lung cancer	2.25e-05	0.000121	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—lung cancer	2.24e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—POMC—lung cancer	2.23e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP9—lung cancer	2.23e-05	0.00012	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—lung cancer	2.22e-05	0.00012	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL2—lung cancer	2.22e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CDKN1A—lung cancer	2.22e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—lung cancer	2.22e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTEN—lung cancer	2.22e-05	0.00012	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—lung cancer	2.21e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—BRAF—lung cancer	2.2e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6R—lung cancer	2.18e-05	0.000117	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CREBBP—lung cancer	2.17e-05	0.000117	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—lung cancer	2.17e-05	0.000117	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCND1—lung cancer	2.16e-05	0.000117	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—lung cancer	2.16e-05	0.000117	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—JUN—lung cancer	2.16e-05	0.000117	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ENO1—lung cancer	2.15e-05	0.000116	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—EGFR—lung cancer	2.14e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	2.13e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MDM2—lung cancer	2.13e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—RAF1—lung cancer	2.12e-05	0.000114	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EP300—lung cancer	2.11e-05	0.000114	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP9—lung cancer	2.1e-05	0.000113	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ERBB2—lung cancer	2.1e-05	0.000113	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CDKN1A—lung cancer	2.09e-05	0.000113	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTEN—lung cancer	2.09e-05	0.000113	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAP2K1—lung cancer	2.07e-05	0.000112	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CB—lung cancer	2.07e-05	0.000112	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MTOR—lung cancer	2.07e-05	0.000112	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CD—lung cancer	2.06e-05	0.000111	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SRC—lung cancer	2.05e-05	0.000111	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—lung cancer	2.05e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	2.04e-05	0.00011	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—lung cancer	2.04e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—KRAS—lung cancer	2.02e-05	0.000109	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—lung cancer	2e-05	0.000108	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EP300—lung cancer	1.99e-05	0.000107	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCL8—lung cancer	1.99e-05	0.000107	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—lung cancer	1.98e-05	0.000107	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NRAS—lung cancer	1.98e-05	0.000107	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—HRAS—lung cancer	1.97e-05	0.000107	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SRC—lung cancer	1.94e-05	0.000105	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP2E1—lung cancer	1.93e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—lung cancer	1.92e-05	0.000104	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NQO1—lung cancer	1.91e-05	0.000103	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—lung cancer	1.9e-05	0.000103	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL2—lung cancer	1.9e-05	0.000102	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAPK3—lung cancer	1.89e-05	0.000102	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—lung cancer	1.89e-05	0.000102	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—lung cancer	1.89e-05	0.000102	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—lung cancer	1.87e-05	0.000101	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NRAS—lung cancer	1.86e-05	0.000101	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	1.85e-05	0.0001	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCND1—lung cancer	1.85e-05	9.99e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—JUN—lung cancer	1.85e-05	9.97e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MDM2—lung cancer	1.85e-05	9.96e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—lung cancer	1.84e-05	9.93e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—RAF1—lung cancer	1.84e-05	9.92e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.82e-05	9.82e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EGFR—lung cancer	1.8e-05	9.71e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP9—lung cancer	1.8e-05	9.7e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.8e-05	9.69e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MTOR—lung cancer	1.8e-05	9.69e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CDKN1A—lung cancer	1.79e-05	9.66e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTEN—lung cancer	1.79e-05	9.64e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAPK3—lung cancer	1.79e-05	9.63e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—lung cancer	1.74e-05	9.41e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—lung cancer	1.74e-05	9.37e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.73e-05	9.31e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—STK11—lung cancer	1.72e-05	9.28e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.72e-05	9.25e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EP300—lung cancer	1.7e-05	9.19e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KRAS—lung cancer	1.7e-05	9.18e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EGFR—lung cancer	1.7e-05	9.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.67e-05	8.99e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SRC—lung cancer	1.66e-05	8.94e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—lung cancer	1.65e-05	8.91e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2—lung cancer	1.65e-05	8.9e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—lung cancer	1.64e-05	8.85e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—lung cancer	1.61e-05	8.71e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCND1—lung cancer	1.61e-05	8.67e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—JUN—lung cancer	1.6e-05	8.66e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KRAS—lung cancer	1.6e-05	8.65e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—lung cancer	1.6e-05	8.62e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NRAS—lung cancer	1.59e-05	8.6e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTP1—lung cancer	1.59e-05	8.59e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CA—lung cancer	1.56e-05	8.43e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP9—lung cancer	1.56e-05	8.42e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	1.56e-05	8.39e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTEN—lung cancer	1.55e-05	8.37e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CAT—lung cancer	1.55e-05	8.36e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK3—lung cancer	1.53e-05	8.24e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.51e-05	8.17e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—lung cancer	1.51e-05	8.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCB1—lung cancer	1.51e-05	8.13e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—lung cancer	1.49e-05	8.01e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TYMS—lung cancer	1.48e-05	7.99e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EP300—lung cancer	1.48e-05	7.98e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CA—lung cancer	1.47e-05	7.95e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTM1—lung cancer	1.46e-05	7.89e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EGFR—lung cancer	1.45e-05	7.84e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HRAS—lung cancer	1.45e-05	7.8e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SRC—lung cancer	1.44e-05	7.76e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—lung cancer	1.43e-05	7.69e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—lung cancer	1.4e-05	7.56e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—lung cancer	1.39e-05	7.49e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP1A1—lung cancer	1.39e-05	7.48e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NRAS—lung cancer	1.38e-05	7.47e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—lung cancer	1.38e-05	7.47e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ERCC2—lung cancer	1.38e-05	7.42e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KRAS—lung cancer	1.37e-05	7.4e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HRAS—lung cancer	1.36e-05	7.36e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK3—lung cancer	1.33e-05	7.15e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—lung cancer	1.31e-05	7.04e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—lung cancer	1.29e-05	6.96e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—lung cancer	1.28e-05	6.89e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EGFR—lung cancer	1.26e-05	6.81e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.26e-05	6.8e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—lung cancer	1.22e-05	6.58e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—lung cancer	1.2e-05	6.49e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KRAS—lung cancer	1.19e-05	6.43e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA1—lung cancer	1.19e-05	6.42e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HRAS—lung cancer	1.17e-05	6.29e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—lung cancer	1.12e-05	6.02e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	1.1e-05	5.91e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—lung cancer	1.09e-05	5.86e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—lung cancer	1.06e-05	5.71e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—POMC—lung cancer	1.03e-05	5.58e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—lung cancer	1.03e-05	5.56e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HRAS—lung cancer	1.01e-05	5.46e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CREBBP—lung cancer	1.01e-05	5.43e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—lung cancer	9.7e-06	5.23e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CD—lung cancer	9.55e-06	5.15e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALB—lung cancer	9.43e-06	5.09e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—lung cancer	8.95e-06	4.82e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CB—lung cancer	8.33e-06	4.49e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTGS2—lung cancer	8.25e-06	4.45e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTEN—lung cancer	7.2e-06	3.88e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—EP300—lung cancer	6.86e-06	3.7e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CA—lung cancer	5.08e-06	2.74e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—lung cancer	4.15e-06	2.24e-05	CbGpPWpGaD
